Table 1.
General characteristics of all enrolled cancer patients (n = 186)
| Opioid group (n = 86) | Control (n = 100) | p value | |
|---|---|---|---|
| Age, years | 55.74 ± 9.91 | 56.86 ± 8.35 | 0.41 |
| Sex | – | – | 0.64 |
| Female | 24(28%) | 31(31%) | – |
| Male | 62(72%) | 69(69%) | – |
| Cancer type | |||
| Lung cancer | 39(45%) | 52(52%) | 0.37 |
| Liver cancer | 12(14%) | 7(7%) | 0.12 |
| Gastric cancer | 11(13%) | 12(12%) | 0.87 |
| Colorectal cancer | 9(10%) | 12(12%) | 0.74 |
| Pancreatic cancer | 7(8%) | 8(8%) | 0.97 |
| Esophageal cancer | 4(5%) | 5(5%) | 0.91 |
| Other | 4(5%) | 4(4%) | 0.83 |
| Cancer staging | |||
| I | 1(1%) | 1(1%) | 0.91 |
| II | 2(2%) | 3(3%) | 0.78 |
| III | 17(20%) | 25(25%) | 0.39 |
| IV | 66(77%) | 71(71%) | 0.38 |
| ECOG | |||
| 0 | 12(14%) | 20(20%) | 0.28 |
| 1 | 65(76%) | 76(76%) | 0.95 |
| 2 | 9(10%) | 4(4%) | 0.08 |
| Body mass index (BMI, kg/m2) | 21.42 ± 3.06 | 22.22 ± 2.64 | 0.06 |
| Total protein (g/l) | 66.05 ± 7.61 | 68.02 ± 6.57 | 0.06 |
| Pain management | |||
| Oxycodone | 86(100%) | NA | NA |
| Dose (mg/day) | 28.95 ± 22.96 | NA | NA |
| Usage days | 27.64 ± 30.02 | NA | NA |
There were no significant differences in age, gender, tumor type and stage, ECOG score, BMI, and total protein between the two tumor groups. Data are presented as the mean ± SD or n (%)
NA not applicable
p values are for comparisons between the opioid and control group